G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 99 filers reported holding G1 THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.35 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,475 | +32.0% | 19,082 | +128.1% | 0.00% | – |
| Q2 2023 | $20,809 | +62.4% | 8,364 | +74.5% | 0.00% | – |
| Q1 2023 | $12,814 | -1.4% | 4,793 | +94.5% | 0.00% | – |
| Q4 2022 | $13,000 | -87.6% | 2,464 | -70.8% | 0.00% | – |
| Q3 2022 | $105,000 | +356.5% | 8,427 | +87.0% | 0.00% | – |
| Q2 2022 | $23,000 | -88.1% | 4,507 | +396.4% | 0.00% | – |
| Q1 2022 | $193,000 | +3116.7% | 908 | +62.7% | 0.00% | – |
| Q4 2021 | $6,000 | -71.4% | 558 | -65.9% | 0.00% | – |
| Q3 2021 | $21,000 | -67.2% | 1,636 | -43.5% | 0.00% | – |
| Q2 2021 | $64,000 | -74.4% | 2,896 | -72.2% | 0.00% | -100.0% |
| Q1 2021 | $250,000 | +290.6% | 10,402 | +192.1% | 0.00% | – |
| Q4 2020 | $64,000 | +326.7% | 3,561 | +447.8% | 0.00% | – |
| Q2 2020 | $15,000 | -63.4% | 650 | -82.5% | 0.00% | – |
| Q1 2020 | $41,000 | – | 3,704 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cormorant Asset Management, LP | 994,287 | $19,041,000 | 1.55% |
| HHLR ADVISORS, LTD. | 949,431 | $18,182,000 | 0.75% |
| BB BIOTECH AG | 671,925 | $12,867,000 | 0.41% |
| Rhenman & Partners Asset Management AB | 172,820 | $3,310,000 | 0.38% |
| Birchview Capital, LP | 15,000 | $287,000 | 0.27% |
| Rock Springs Capital Management LP | 100,000 | $1,915,000 | 0.09% |
| SECOR Capital Advisors, LP | 32,591 | $624,000 | 0.08% |
| MARSHALL WACE, LLP | 386,510 | $7,402,000 | 0.08% |
| SIGNATUREFD, LLC | 37,942 | $727,000 | 0.07% |
| A.R.T. Advisors, LLC | 38,125 | $730,000 | 0.05% |